Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Pharmaceutical Industries Ltd. reported Q3 2022 revenues of $3.6 billion, an 8% decline from Q3 2021. GAAP diluted EPS was $0.05, while non-GAAP EPS was $0.59. The company revised its 2022 revenue outlook to $14.8-$15.4 billion due to foreign exchange headwinds. AUSTEDO and AJOVY showed strong growth, with AUSTEDO's U.S. revenues increasing by 30%. However, revenues from generic products declined in North America, and the company faced significant foreign exchange impacts. Teva expects a non-GAAP tax rate of 12%-14% for 2022.

Teva Pharmaceuticals has released new findings from the ARC-HD trial, an open-label extension study assessing the long-term effects of AUSTEDO (deutetrabenazine) for chorea associated with Huntington's Disease. The study highlighted a similar safety profile to earlier trials, with over 90% medication compliance and significant reductions in mean chorea scores. The results, involving 119 patients, affirm AUSTEDO's efficacy in maintaining chorea control over approximately three years. These findings enhance the treatment landscape for Huntington's Disease, which affects around 35,000 individuals in the U.S.

Teva Pharmaceuticals has reached a settlement agreement with the Attorney General of Arkansas regarding price-fixing claims, agreeing to pay $931,000. This marks the fourth settlement in similar litigation, having previously settled with Mississippi, Louisiana, and Georgia. Teva denies the allegations but aims to resolve legacy litigation while focusing on delivering quality medicines. The company is in talks with additional states for further settlements.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) plans to release its third quarter 2022 financial results on November 3, 2022, at 7:00 a.m. ET. A conference call and live webcast will follow at 8:00 a.m. ET. Investors must register in advance to participate. The event will be available for replay on Teva's website within 24 hours post-call. Teva is recognized for its extensive portfolio of over 3,500 products, impacting 200 million patients daily, and has a strong commitment to innovation in specialty and biopharmaceuticals.

Teva Pharmaceuticals has launched a significant 3-year longitudinal study to explore the effects of tardive dyskinesia and treatment with AUSTEDO (deutetrabenazine). This Phase 4 multicenter study aims to gather real-time data on the impact of TD, impacting one in four patients on certain mental health medications. The study will collect comprehensive information on the progression of TD, capturing both patient and clinician-reported outcomes. Approximately 600 patients will be enrolled across 45 centers in the U.S.

Teva Pharmaceuticals has reached a settlement with the Attorney General of Georgia, agreeing to pay $3.346 million to resolve price-fixing claims. This settlement will lead to the dismissal of all claims against Teva and its affiliates once paid. Teva has previously settled similar litigation with Mississippi and Louisiana. The company continues to deny the allegations but remains committed to compliance and robust antitrust training. Teva aims to focus on delivering quality medicines while addressing legacy litigation matters, including discussions with other states regarding settlements.

Teva Pharmaceuticals has launched the Honestly HD website to assist the Huntington's Disease (HD) community in understanding chorea symptoms and communicating with healthcare providers. The site offers resources for managing HD chorea, which affects 90% of those with HD, potentially impacting daily life. Alongside the website, a Twitter channel and Facebook community have been introduced to foster support. Teva emphasizes its commitment to helping patients navigate the challenges posed by this degenerative disease.

Teva Pharmaceutical Industries has presented two studies at the Migraine Trust International Symposium (MTIS) in London, showcasing the efficacy of AJOVY (fremanezumab) for treating migraine in patients with co-morbid depression and anxiety. Results showed over 50% reduction in monthly migraine attacks in patients taking AJOVY compared to placebo. The studies highlight the importance of addressing psychiatric comorbidities in migraine treatment. Teva aims to provide personalized treatment options, with ongoing research including the UNITE study assessing AJOVY's effectiveness in managing chronic migraine with major depressive disorder.

Teva Pharmaceuticals announced promising results from the CONNECT1 study, comparing the ProAir Digihaler to standard albuterol inhalers for asthma management. Patients using the Digihaler saw an 85.3% increase in improving asthma control after three months. The study, involving 333 participants, highlighted that those with the Digihaler had better adherence discussions with physicians and experienced fewer SABA inhalations. Additionally, 61% of Digihaler users achieved well-controlled asthma compared to 55% in the standard care group. The findings underscore the potential of digital tools in asthma management.